Is Verteporfin registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 0 valid registrations of Verteporfin.

Is Verteporfin approved by the US FDA?

Drugs@FDA lists 1 application product line for Verteporfin, including VISUDYNE (Prescription).

Is Verteporfin authorised in the European Union?

EMA lists 1 centrally authorised medicine containing Verteporfin: Visudyne.

Are there safety signals or safety updates for Verteporfin?

US FDA: 1 entry (latest 2021-07-09).

Active substance

Verteporfin

SFDA 1
US FDA 1
EMA 1
Health Canada 1
Safety 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
VISUDYNE 15MG POWDER FOR INFUSION	15 mg	Powder for solution for infusion · Intravenous use	1 Vial	SAR 5422.85	NCE · Prescription	NOVARTIS	Withdrawn by MAH · Not Marketed

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
VISUDYNE	15MG/VIAL	injectable · injection	BAUSCH LOMB IRELAND	Prescription	12 Apr 2000

EMA European Union — centrally authorised medicines

Visudyne CHEPLAPHARM Arzneimittel GmbH · Authorised · authorised 27 Jul 2000 · ATC S01LA01

Therapeutic indication (EMA)

Visudyne is indicated for the treatment of: adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or; adults with subfoveal choroidal neovascularisation secondary to pathological myopia.

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
VISUDYNE	02242367	15 MG / VIAL	POWDER FOR SOLUTION · INTRAVENOUS	CHEPLAPHARM ARZNEIMITTEL GMBH

Safety signals and safety-related labeling changes

US FDA 9 Jul 2021 VISUDYNE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations

All safety entries for verteporfin →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.